Dr. Estela Rodriguez (@Latinamd) ranks #7 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 39 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: DeLLphi-305, LIBRETTO-432, WU-KONG28. CMS Open Payments lists $51,016 in 2025 general payments.
At a Glance
- 37 posts naming a trial in 2026
- 19 trials discussed by name
- Lung Cancer: US #7, Global #17 · 39 physicians engaged
- CMS Open Payments lists $51,016 in 2025 general payments.
This Month
What Dr. Estela Rodriguez has posted in the last 30 days. Updated November 10, 2026.
🇪🇸#ESMO26 concurrent @NEJM #OptiTropLung06 : Sac-TMT+pembro in PDL1 neg driver negative NSCLC publication👇 https://t.co/MTktQqSTlj
#DeLLPhi305 Low US enrollment in this pivotal #SCLC trial is NOT surprising. Regulatory hurdles, costs & complexity push sponsors to conduct trials faster ex-US—even for drugs destined to be used at greater rates by US patients. Why it matters: ▶️ Less evidence on implementation & AEs in diverse populations ▶️ Fewer opportunities for US investigators to shape drug development early We need faster, more inclusive trials! 🔬#clinicaltrials #ESMO26 @SclcSMASHERS @GlopesMd
🇪🇸 #ESMO26 | Top Lung Abstracts 🫁 🚨 OPTITROP-Lung06: Phase III trial in PD-L1–negative, driver-negative nonsquamous NSCLC: 🔥 Median PFS: 15.0 vs 5.7 months 📉 HR 0.49 — 51% reduction in risk of progression/death 🎯 DOR: 13.6 vs 6.8 months 📊 12-mo OS: 77.6% vs 66.4% (immature data) ▶️ I wouldn’t call this a “chemo-free” regimen because the toxicity of an ADC is similar to chemo—> but this many be a potential option for this hard to treat PDL1 neg population. ▶️Could this change the 1L landscape? 👀maybe? but I would hope for a bigger survival advantage….data immature … #LungCancer #LCSM #ADC
🚨#ESMO26 and last but not least Top Lung Abstract goes to the new Diva 💃 of #KRASG12C #lungcancer! #KRASCENDO1: Phase III #Divarasib vs sotorasib/adagrasib after prior chemotherapy for #KRASG12C NSCLC 📈 PFS: 9.8 vs 5.7 mo (HR 0.58) 🔥 OS: ~18 vs 12 mo (HR 0.56) 🎯 ORR: 58.4% vs 32.3% ⚠️ Grade 3–4 TRAEs: 24.6% vs 34.5% 🏆This is clearly practice changing with a much better tolerated drug and fewer side effects ( although still GI toxicity) compared to current standard for this high-risk population. 🤔Still some questions about exclusion of untreated brain mets and low number of adagrasib treated pts in control arm #lcsm @KRASKickers
🚨 #ESMO26 | Top Lung Abstracts 🫁 OptiTROP-Lung04 (Phase III- China only trial) Significant mOS 8.5 mo advantage for sac-TMT, a TROP2 ADC, after EGFR-TKI progression in EGFR-mutant NSCLC🫁 vs chemo! 📊 Median OS: 25.9 vs 17.4 months 🔥 HR 0.69 — 31% lower risk of death ⚠️ AEs- cytopenias, stomatitis, opthal, ILD 👉🏽Competes w Dato-DXd already approved in this EGFR+ population based on Tropion-Lung05, Lung01 👉🏽Global validation and treatment-sequencing questions remain. @EGFRResisters #LCSM #LungCancer #ESMO26
🚨 #ESMO26 | Top Lung Abstracts🫁 PERSEE: Phase 3 🇫🇷 study of pembrolizumab alone vs chemo+pembro for PD-L1-high 🔥 PFS: 16.1 vs 6.9 mo (HR 0.56) 🎯 ORR: 77.5% vs 50.3% ⚠️ Early progression: 5.8% vs 26.5% 📊 OS: 50.2 vs 29.9 mo (HR 0.77; NS) 👉🏽 Maybe more is better for select patients 👉🏽Benefit persisted even with PD-L1 ≥90%—but grade ≥3 TRAEs increased (53.8% vs 19.3%). More disease control but more toxicity. #lcsm #immunotherapy
Who Amplifies Dr. Estela Rodriguez
Physicians who reposted Dr. Estela Rodriguez’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #7 | #17 | 39 | 67 | Full ranking |
What Colleagues Are Saying About Dr. Estela Rodriguez
2026 posts by fellow physicians that mention @Latinamd, quoted word for word.
In Small Cell Lung Cancer “Challenging Case” discussion with @Latinamd & @drshieldsmd: ✅ Limited & Extensive Stg ✅ MAVERICK data ✅ Supportive care ✅ Maintenance & Sequencing Full 🗣️: ⭐️ https://t.co/0hNNzXoEt4 ⭐️ “Oncology Brothers” podcast #OncTwitter @OncoAlert https://t.co/UWG7SeYzoB
Dr. @Latinamd at #WCLC26 discusses @IASLC Thoracic Circle - discussion groups to connect and collaborate, available to all members. https://t.co/82ylbCEp2K
Dr @Latinamd highlights the role and potential of @IASLC Thoracic Circle in building community across the thoracic oncology world! Just like the #BTSArmy & #Boricuas everywhere find community across 🌎 Best part? IT’S FREE for IASLC members! #WCLC26 #PuertoRico https://t.co/bvv8cwbPrZ
How can clinicians make amivantamab plus lazertinib easier to deliver for patients with newly diagnosed EGFR-mutant non-small cell lung cancer (NSCLC)? Recording live at the 2026 World Conference on Lung Cancer (WCLC) in Seoul, South Korea, Estelamari Rodriguez @Latinamd speaks with Wade Iams, MD, from Tennessee Oncology @WadeIams , and Luis Raez, MD, from Memorial Cancer Institute @MCIStrong @mhshospital @FLASCO_ORG @OLACANCER1 about selecting first-line combination therapy and managing amivantamab plus lazertinib in clinical practice. #lungcancer #lcsm https://t.co/pt4mIbIGiH
Trials Dr. Estela Rodriguez Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| DeLLphi-305 | 5 | #14 of 86 | Oct 25, 2026 |
| LIBRETTO-432 | 5 | #9 of 53 | May 31, 2026 |
| WU-KONG28 | 3 | #13 of 29 | Oct 22, 2026 |
| MAVERICK (SWOG S1827) | 3 | #16 of 33 | Sep 12, 2026 |
| OptiTROP-Lung06 | 2 | #14 of 29 | Oct 27, 2026 |
| PERSEE (GFPC 01-2020) | 2 | #20 of 34 | Oct 25, 2026 |
| SAFFRON | 2 | #19 of 50 | Oct 25, 2026 |
| ADAURA | 2 | #18 of 41 | Sep 14, 2026 |
| RASolute 302 | 2 | #38 of 73 | May 31, 2026 |
| PROTEUS | 2 | #29 of 56 | May 31, 2026 |
| HARMONi-6 | 2 | #27 of 74 | May 31, 2026 |
| KRASCENDO-1 | 1 | #34 of 49 | Oct 25, 2026 |
| OptiTROP-Lung04 | 1 | #9 of 18 | Oct 25, 2026 |
| SARON | 1 | #12 of 22 | Oct 25, 2026 |
| PAPILLON | 1 | #14 of 26 | Sep 14, 2026 |
| ARTEMIS-008 | 1 | #9 of 20 | Sep 13, 2026 |
| TAISHAN-302 | 1 | #18 of 26 | Sep 13, 2026 |
| CROWN | 1 | #11 of 36 | May 29, 2026 |
| CHRYSALIS-2 | 1 | #5 of 14 | May 29, 2026 |
Dr. Estela Rodriguez on DeLLphi-305
#DeLLPhi305 Low US enrollment in this pivotal #SCLC trial is NOT surprising. Regulatory hurdles, costs & complexity push sponsors to conduct trials faster ex-US—even for drugs destined to be used at greater rates by US patients. Why it matters: ▶️ Less evidence on implementation & AEs in diverse populations ▶️ Fewer opportunities for US investigators to shape drug development early We need faster, more inclusive trials! 🔬#clinicaltrials #ESMO26 @SclcSMASHERS @GlopesMd
🔥🔥#ESMO26 Top Thoracic Abstracts: #DeLLphi305: Phase III (n=563): Tarlatamab + Durvalumab vs Durvalumab as 1L maintenance after chemo-IO in ES-SCLC Definitely practice changing if we are able to deliver to more pts in the community , moving tarlatamab 1L maintenance ▶️Median OS: 21.1 vs 12.7 months (HR 0.42) 🔥 ▶️12-month OS: 79.4% vs 53.3% ▶️Median PFS: 7.4 vs 1.9 months (HR 0.34) ▶️ORR: 26.4% vs 4.1% ⚠️ Grade ≥3 AEs: 46.8% vs 40.6%; CRS 49.6% (mostly low grade). #lcsm @SclcSMASHERS
💃🍷 Eating tapas while watching the TOP #lungcancer abstracts roll in from #ESMO26 in Madrid! 🔬 From today’s DeLLphi-305 results with tarlatamab in SCLC to upcoming data on KRAS G12C, EGFR/MET combinations & next-gen ADCs in NSCLC — so much to look forward to! What are YOU most excited about? 👇 #LungCancer #LCSM #ESMO26 🇪🇸 @myESMO
Dr. Estela Rodriguez on LIBRETTO-432
#ASCO26 Plenary LBA3: #LIBRETTO-432 Adjuvant #selpercatinib vs placebo in RET+ Stage IB-IIIA NSLC Presented by Dr Johnathan Goldman @UCLA 🔹 151 pts with resected stage IB-IIIA RET fusion+ NSCLC 🔹 2-year EFS: ✅ Stage II-IIIA: 92% vs 61% (HR 0.17) ✅ ITT population: 94% vs 70% https://t.co/vqDdIcenfA
#ASCO26 Excellent discussion by @christine_lovly on #LIBRETTO432: adjuvant selpercatinib sets a new standard in resected RET+ #NSCLC. Key implications: 🔹 RET testing now essential in early-stage disease 🔹 Raises key questions on about access to care, financial toxicity, https://t.co/xQCyRo0UZB
#ASCO26 Excellent discussion by @christine_lovly on #LIBRETTO432: adjuvant selpercatinib sets a new standard in resected RET+ #NSCLC. Key implications: 🔹 RET testing now essential in early-stage disease 🔹 Expands precision oncology into curative setting 🔹 Raises key questions https://t.co/x3YjIuZ466
Dr. Estela Rodriguez on WU-KONG28
🚨Great news for patients with #EGFRex20ins #lungcancer #Sunvozertinib finally available for dispensation in the US following FDA approval in July 2025. 📌 Approved for previously treated patients based on WU-KONG1B: 🔹 ORR: 46% (95% CI 35–57) 🔹 DoR: 11.1 mo (95% CI 8.2–NE) 📊 In the WU-KONG28 Phase III trial, first-line sunvozertinib vs carbo/pem (n=324) showed: 🔹 ORR: 59% vs 31% 🔹 DoR: 11.2 vs 7.1 mo 🔹 PFS: 10.3 vs 7.5 mo (HR 0.65) 🔹 12-mo PFS: 46% vs 27% 💊 200mg po daily ⚠️ Monitor for ILD/pneumonitis, GI and skin toxicity, ocular toxicity ⚠️ Diarrhea: 75% G3+: 5%) @EGFRResisters
And the concomitant #ASCO26 publications are out: #WU-KONG28 Ph3 trial of 1L #Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations ➡️ mPFS 10.3 vs 7.5 mos ⬆️ ORR 58.9% vs 31.1% ⚠️ AEs renal, GI, anemia 👎 FDA approved in July 2025 but not yet available in the US for https://t.co/gLoBx6Fpz6
RT @HHorinouchi: 🆙 @OncoAlert #ASCO26 #LCSM 🔝🔟Abstracts Leads: @HHorinouchi @UOzkerim @WeOncologists 1 HARMONi-6 2 LIBRETTO-432 3 WU-KONG28…
Dr. Estela Rodriguez on MAVERICK (SWOG S1827)
🧠 #WCLC26 #MAVERICK (SWOG S1827) finally answers a long-standing question: PCI vs brain MRI surveillance in SCLC. 🧠PCI reduced brain metastases, but PFS was not significantly different, while Grade ≥3 toxicity was higher with PCI. 🧠MRI surveillance resulted in lower cognitive failure–free survival (CFFS) than PCI, but no difference in PFS (although overall survival analysis pending) 👉🏽 Study included majority limited stage (68%) SCLC. 👉🏽 A potential practice-changing shift toward MRI surveillance and treatment of CNS disease when it emerges. 🧠 @IASLC @LUNGevity @SclcSMASHERS #lcsm
🧠 #WCLC26 MAVERICK (SWOG S1827) finally answers a long-standing question: PCI vs brain MRI surveillance in SCLC. Study included majority limited stage (68%) SCLC. PCI reduced brain metastases, but PFS was not significantly different, while Grade ≥3 toxicity was higher with PCI. 👉🏽 A potential practice-changing shift toward MRI surveillance and treatment of CNS disease when it emerges. 🧠 @IASLC @LUNGevity @SclcSMASHERS #lcsm
🧠 #WCLC26 MAVERICK (SWOG S1827) finally answers a long-standing question: PCI vs brain MRI surveillance in SCLC. Study included majority limited stage (68%) SCLC. 🧠PCI reduced brain metastases, but PFS was not significantly different, while Grade ≥3 toxicity was higher with PCI. 🧠MRI surveillance resulted in lower cognitive failure–free survival (CFFS) than PCI, but no difference in PFS (although overall survival analysis pending) 👉🏽 A potential practice-changing shift toward MRI surveillance and treatment of CNS disease when it emerges. 🧠 @IASLC @LUNGevity @SclcSMASHERS #lcsm
Dr. Estela Rodriguez on OptiTROP-Lung06
🇪🇸#ESMO26 concurrent @NEJM #OptiTropLung06 : Sac-TMT+pembro in PDL1 neg driver negative NSCLC publication👇 https://t.co/MTktQqSTlj
🇪🇸 #ESMO26 | Top Lung Abstracts 🫁 🚨 OPTITROP-Lung06: Phase III trial in PD-L1–negative, driver-negative nonsquamous NSCLC: 🔥 Median PFS: 15.0 vs 5.7 months 📉 HR 0.49 — 51% reduction in risk of progression/death 🎯 DOR: 13.6 vs 6.8 months 📊 12-mo OS: 77.6% vs 66.4% (immature data) ▶️ I wouldn’t call this a “chemo-free” regimen because the toxicity of an ADC is similar to chemo—> but this many be a potential option for this hard to treat PDL1 neg population. ▶️Could this change the 1L landscape? 👀maybe? but I would hope for a bigger survival advantage….data immature … #LungCancer #LCSM #ADC
Dr. Estela Rodriguez on PERSEE (GFPC 01-2020)
🚨 #ESMO26 | Top Lung Abstracts🫁 PERSEE: Phase 3 🇫🇷 study of pembrolizumab alone vs chemo+pembro for PD-L1-high 🔥 PFS: 16.1 vs 6.9 mo (HR 0.56) 🎯 ORR: 77.5% vs 50.3% ⚠️ Early progression: 5.8% vs 26.5% 📊 OS: 50.2 vs 29.9 mo (HR 0.77; NS) 👉🏽 Maybe more is better for select patients 👉🏽Benefit persisted even with PD-L1 ≥90%—but grade ≥3 TRAEs increased (53.8% vs 19.3%). More disease control but more toxicity. #lcsm #immunotherapy
#ESMO26 #PERSEE Concurrent publication via https://t.co/eKRg5pX041
Dr. Estela Rodriguez on SAFFRON
#ESMO26 🇪🇸 Top Lung Abstracts 🫁 #SAFFRON Phase 3 study of #savolitinib + osimertinib vs. platinum–pemetrexed for MET- driven resistance post osimertinib (N=338) 🎯 MET IHC 3+/ Amp (FISH)>10 🎯 PFS: 7.6 vs 5.4 mo (HR 0.55) 🎯 OS: 17.8 vs 12.9 mo (HR 0.68) 🎯 ORR: 51% vs 27% ⚠️ AEs: Edema & GI toxicity 👉🏽 Clinical Challenge - Although MET resistance post osi can occur 20-30%, it is hard to test for this prospectively in clinic- requires repeat biopsy🔪 #LCSM #LungCancer @EGFRResisters
Concurent #SAFFRON #savolitinib @NEJM publication https://t.co/qPSi0on0rq
Dr. Estela Rodriguez on ADAURA
#WCLC26 Presidential Symposium Day 2 #ADAURA: Adjuvant osimertinib — exploratory 8-year OS landmark update 🎙@DrRoyHerbst 🎯8-y OS 74% (osimertinib) vs 58% (placebo; HR 0.53); Stage IB-IIIA: 79% vs 64% (HR 0.52) 🎯Ex19del shows stronger OS benefit (HR 0.45) vs L858R (HR 0.72) 👉🏽remaining questions❓ -what is role of chemo -can we de-escalate treatment @iaslc @EGFRSummit @EGFRResisters
#ADAURA 8 yr update concurrent @JTOonline publication-https://t.co/lT0xSVxZEF
Dr. Estela Rodriguez’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Here are my own #ASCO26 Top 10 🫁 Lung Cancer Abstracts based on potential clinical impact — although there is so much exciting and innovative science being presented across the field. Looking forward to the discussions, debates, and future directions these data may inspire. #LungCancer
Does immunotherapy reduce incidence of brain 🧠 Mets in ES-SCLC❓this large prospective study from China suggests it does not. Brain Mets in chemoIO 29% vs 23% in chemo only group. - It it because pts live longer? - would the addition of tarlatamab change this pattern? 👇🏽 Incidence, Risk Factors, and Impact of Immunotherapy on Brain Metastasis in Extensive-Stage Small Cell Lung Cancer Without Baseline Brain Involvement | JCO Oncology Practice https://t.co/HmB8hdRjzo @LauraAlderMD @drshieldsmd
#ELCC26 Another population-based study showing the clear benefit of #lungcancer screening in adults 40-74 including never smokers in China. N=12,000 followup 7 yrs ⬇️Significantly lower risk of LC deaths (HR 0.45) ⬆️ Increased mortality benefit in women (HR 0.28) ⬆️more Stage I LC cases compared to control population. (85% vs 25%) #screeningsaveslives 🎙️Dr. Caichen Li
#WCLC26 @IASLC Presidential Symposium 1 Abstracts are out and here is why they matter: ▶️PL02.01: MAVERICK: Could fundamentally change the role of PCI in SCLC, particularly in the MRI-surveillance era. ▶️ PL02.03: TAISHAN-302 Tam-Peli, a B7-H3 ADC, vs topotecan in relapsed SCLC Major test of B7-H3 ADCs in SCLC; potentially another option ▶️ PL02.04: ARTEMIS-008 — Risvutatug rezetecan vs topotecan in relapsed SCLC 1st reported positive phase III OS study of a B7-H3 ADC in SCLC. ▶️ PL02.06: EVOKE-03 Sacituzumab govitecan + pembro in PD-L1 TPS ≥50% metastatic NSCLC Tests whether adding a TROP-2 ADC to immunotherapy can improve first-line treatment beyond pembrolizumab alone- would magnitude of benefit overcome extra toxicity ? #lcsm #thoraciconcology
🔥🔥off the press @ASCO Living Guideline update: Stage IV NSCLC without driver alterations 2026.3.1 Via @JCO_ASCO ☑Latest update incorporating new evidence for ICI-based regimens in stage IV NSCLC ➡️Updates on : retifanlimab Ivonescimab, plus BAP BRAIN (avastin+pemetrexed for 🧠Mets) 🎙Dr. Lyudmila Bazhenova et al. @BrunaPellini @HHorinouchi @JFreemanDaily Dr Natasha Leighl @ns_chd 📖 https://t.co/v2ZiSx6eoV
Industry Payments
CMS Open Payments · 2025 general payments
$51,016 across 120 payments